Advanced in Sertoli-Leydig Cell Tumor

Dr. Rebecca L. Moroose

Oncology | Hematology Oncology | Hematology
22 W Underwood St, 
Orlando, FL 
Advanced in Sertoli-Leydig Cell Tumor
22 W Underwood St, 
Orlando, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rebecca Moroose is an Oncologist and a Hematologist Oncology provider in Orlando, Florida. Dr. Moroose is rated as an Advanced provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and Ovarian Carcinosarcoma.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO

Locations

22 W Underwood St, Orlando, FL 32806

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Pertuzumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan Versus Treatment of Physician Choice in Patients With Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments
Enrollment Status: Completed
Publish Date: June 15, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancer
Enrollment Status: Completed
Publish Date: August 12, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor
Enrollment Status: Completed
Publish Date: May 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies
Enrollment Status: Approved_for_marketing
Publish Date: October 31, 2017
Intervention Type: Drug
View 6 Less Clinical Trials

13 Total Publications

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 01, 2024
Similar Doctors
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Robert W. Holloway
Gynecologic Oncology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Robert W. Holloway
Gynecologic Oncology | Oncology

Florida Hospital Medical Group Inc

601 E Rollins St, 
Orlando, FL 
 (3.3 miles away)
407-303-2570
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Robert Holloway is a Gynecologic Oncologist and an Oncologist in Orlando, Florida. Dr. Holloway is rated as an Elite provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Holloway is currently accepting new patients.

Distinguished in Sertoli-Leydig Cell Tumor
Dr. James E. Kendrick
Gynecologic Oncology | Oncology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. James E. Kendrick
Gynecologic Oncology | Oncology

Florida Hospital Medical Group Inc

2501 N Orange Ave, Suite 786, 
Orlando, FL 
 (3.3 miles away)
407-303-2422
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

James Kendrick is a Gynecologic Oncologist and an Oncologist in Orlando, Florida. Dr. Kendrick is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Cancer, Sertoli-Leydig Cell Tumor, Vulvectomy, and Hysterectomy. Dr. Kendrick is currently accepting new patients.

Distinguished in Sertoli-Leydig Cell Tumor
Dr. Veronica L. Schimp
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Sertoli-Leydig Cell Tumor
Dr. Veronica L. Schimp
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Orlando Health Medical Group Inc

1400 S Orange Ave, 
Orlando, FL 
 (0.1 miles away)
321-841-6600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Veronica Schimp is a Gynecologic Oncologist and an Oncologist in Orlando, Florida. Dr. Schimp is rated as a Distinguished provider by MediFind in the treatment of Sertoli-Leydig Cell Tumor. Her top areas of expertise are Ovarian Carcinosarcoma, Ovarian Cancer, Malignant Mixed Mullerian Tumor, Virilizing Ovarian Tumor, and Hernia Surgery. Dr. Schimp is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Moroose's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile